FOLH1 and neoplasm: In the [177Lu]Lu-PSMA-617 plus BSoC treatment arm, every one-unit increase in whole-body tumor SUVmean was associated with a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death (43).